Efficacy of azvudine plus dexamethasone in severe hospitalized patients with Omicron infection: a prospective multicenter study
BackgroundAzvudine (AZV), the first Chinese oral anti-coronavirus disease 2019 (COVID-19) drug, has shown substantial clinical benefits to viral clearance and prognosis in patients with mild and common COVID-19. However, there is no evidence in severe hospitalized COVID-19 patients.MethodsIn this mu...
Saved in:
Main Authors: | Meng-Lan Zhang, Xiao-Ying Wei, Nan Su, Jung-Hong Jiang, Guo-Peng Xu, Da-Xiong Zeng |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2024-11-01
|
Series: | Frontiers in Cellular and Infection Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2024.1390098/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Azvudine efficacy in reducing mortality in COVID-19 patients
by: Zhen Zhong, et al.
Published: (2024-12-01) -
Immunophenotyping characteristics and clinical outcome of COVID-19 patients treated with azvudine during the Omicron surge
by: Meihua Qiu, et al.
Published: (2024-11-01) -
Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study
by: Wei Yang, et al.
Published: (2024-12-01) -
Early Versus Delayed Usage of Paxlovid in Severe Omicron‐Infected Patients With Hypoxemia: A Prospective Multiple‐Center Cohort Study
by: Yu‐Ji Wang, et al.
Published: (2024-11-01) -
Characteristics of patients with non-severe infections of different SARS-CoV-2 omicron subvariants in China
by: Wenfang Yuan, et al.
Published: (2024-12-01)